You are here

Product Pipeline

OUR MEDICINES IN DEVELOPMENT

Our priority is researching and developing medicines and vaccines that will benefit patients around the world. We are committed to addressing unmet needs across a number of important therapeutic areas including, Oncology, Inflammation & Immunology, Vaccines, Internal Medicine and Rare Disease, with the goal of delivering innovative products to patients. 

Key Innovative Programs in Registration / Phase 3

Key Biosimilars Programs in Registration / Phase 3

Key Programs in Phase 2

Pipeline date and pdf

Pipeline Snapshot as of April 30, 2019

  • Discovery Projects
  • Phase 1
    34
  • Phase 2
    30
  • Phase 3
    23
  • Registration
    10
  • Total97
 
Compound Name
Indication
Phase
Submission Typesort descending
Compound Type
crisaborole (PF-06940799)
Therapeutic Area:
Inflammation & Immunology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
PDE4 Inhibitor
Go to clinical trial
Atopic Dermatitis (E.U.) Registration New Molecular Entity Small Molecule
somatrogon (PF-06836922)
Therapeutic Area:
Rare Diseases
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Human Growth Hormone Agonist
Go to clinical trial
Adult Growth Hormone Deficiency (Biologic) (ORPHAN - U.S., E.U.) Phase 3 New Molecular Entity Biologic
PF-06651600
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
JAK3
Go to clinical trial
Alopecia Areata (BREAKTHROUGH) Phase 3 New Molecular Entity Small Molecule
fidanacogene elaparvovec (PF-06838435)
Therapeutic Area:
Rare Diseases
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Gene Therapy, coagulation factor IX (F9)
Go to clinical trial
Hemophilia (Biologic) (BREAKTHROUGH, ORPHAN - U.S., E.U., PRIME - E.U.) Phase 3 New Molecular Entity Biologic
PF-06946860
Therapeutic Area:
Internal Medicine
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
Growth Factor Blocker
Go to clinical trial
Cachexia (Biologic) Phase 1 New Molecular Entity Biologic
PF-06650833
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
IRAK4
Go to clinical trial
Rheumatoid Arthritis Phase 2 New Molecular Entity Small Molecule
PF-06480605
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
TNFSF15 Blocker
Go to clinical trial
Ulcerative Colitis (Biologic) Phase 2 New Molecular Entity Biologic
PF-05221304
Therapeutic Area:
Internal Medicine
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Acetyl CoA-Carboxylase (ACC) Inhibitor
Go to clinical trial
Non-Alcoholic Steatohepatitis (NASH) with liver fibrosis (FAST TRACK) Phase 2 New Molecular Entity Small Molecule
Daurismo (glasdegib)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
SMO (smoothened) antagonist
Go to clinical trial
Combo w/ low-dose cytarabine (LDAC) for Acute Myeloid Leukemia (E.U.) Phase 2 New Molecular Entity Small Molecule
aztreonam-avibactam (PF-06947387)
Therapeutic Area:
Hospital (Anti-Infectives)
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
Beta Lactam/Beta Lactamase Inhibitor
Go to clinical trial
Treatment of infections caused by Gram-negative bacteria for which there are limited or no treatment options Phase 3 New Molecular Entity Small Molecule
rivipansel (GMI-1070)
Therapeutic Area:
Rare Diseases
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
Pan-Selectin Antagonist
Go to clinical trial
Acute vaso-occlusive crises associated with sickle cell disease in patients aged 6 years and above (FAST TRACK, ORPHAN - U.S., E.U.) Phase 3 New Molecular Entity Small Molecule
PF-06482077
Therapeutic Area:
Vaccines
Phase:Phase 3
Compound Type:Vaccine
Business Segment:
Biopharma
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Invasive and non-invasive Pneumococcal infections (BREAKTHROUGH) Phase 3 New Molecular Entity Vaccine
talazoparib (MDV3800)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
PARP inhibitor
Go to clinical trial
Germline BRCA Mutated Metastatic Breast Cancer (E.U.) Registration New Molecular Entity Small Molecule
tafamidis meglumine
Therapeutic Area:
Rare Diseases
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
Transthyretin (TTR) Dissociation Inhibitor
Go to clinical trial
Transthyretin familial amyloid polyneuropathy (U.S.) (FAST TRACK, ORPHAN - U.S.) Registration New Molecular Entity Small Molecule
PF-04965842
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
JAK Inhibitor
Go to clinical trial
Atopic Dermatitis (BREAKTHROUGH) Phase 3 New Molecular Entity Small Molecule
PF-06425090
Therapeutic Area:
Vaccines
Phase:Phase 3
Compound Type:Vaccine
Business Segment:
Biopharma
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Primary clostridium difficile infection (FAST TRACK) Phase 3 New Molecular Entity Vaccine
Dekavil
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
IL-10
Go to clinical trial
Rheumatoid Arthritis (Biologic) Phase 2 New Molecular Entity Biologic
lorlatinib (PF-06463922)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
ALK Inhibitor
Go to clinical trial
2nd Line ALK Non-Small Cell Lung Cancer (E.U.) Registration New Molecular Entity Small Molecule